Academic Reading Articles Practice 10 Test 02

A Vaccine hesitancy has become a defining challenge for contemporary public health because it sits in the grey area between acceptance and refusal. The World Health Organization describes it as a delay in accepting, or a reluctance to accept, vaccines even when services are available. That definition matters because it frames hesitancy as a spectrum rather than a binary identity. Many people who hesitate are not committed opponents of vaccination; they may accept certain vaccines yet postpone others, or they may remain uncertain while weighing perceived risks against perceived benefits. Their doubts can be shaped by concerns about safety, questions about effectiveness, or beliefs about personal necessity. At the same time, hesitancy is not only psychological: decisions are also influenced by practical convenience, the visibility of vaccination services, and levels of confidence in institutions. Because it changes across time, place and vaccine type, it cannot be addressed with a single slogan or a uniform campaign.

B One paradoxical driver of hesitancy is the success of vaccination itself. When immunisation programmes work well, they reduce the everyday visibility of diseases such as measles or polio. As a result, some communities begin to perceive infection as a remote threat, while the possibility of side effects—however rare—feels more immediate. This imbalance in risk perception is often described as complacency: the idea that people delay a preventive action because the danger it prevents no longer seems urgent. In sociological terms, vaccination alters the collective memory of disease. Older generations may remember hospital wards filled with children suffering complications, while younger parents may never have witnessed such outcomes. When the disease fades from view, the vaccine can appear less necessary, even though herd immunity depends on sustained high coverage. The irony is that the better the system performs, the easier it becomes for individuals to underestimate what the system is preventing.

C Public health communication has sometimes responded as if hesitancy were simply an information gap. This “deficit model” assumes that if people are given more facts, they will correct misconceptions and comply. Yet research in behavioural science suggests that this approach can misfire. When hesitant individuals feel they are being lectured or pressured, they may experience psychological reactance: a defensive response in which people protect their autonomy by resisting the message and entrenching their prior views. In practice, this means that “more data” can sometimes harden resistance rather than resolve doubt. Alternative strategies aim to reduce confrontation and increase dialogue. Clinicians and outreach workers increasingly use motivational interviewing techniques, which involve asking open questions, listening carefully, and helping individuals clarify their own values and ambivalence. This does not mean withholding evidence; it means presenting information in a way that supports agency, builds rapport, and addresses specific concerns rather than delivering generic statistics.

D In many settings, hesitancy is less about ideology than about logistical barriers. People may intend to vaccinate yet delay because the clinic is far away, opening hours conflict with work, or booking systems are confusing. For families on tight budgets, the cost of transport or the loss of wages from taking time off can be decisive. Even minor frictions—long queues, repeated paperwork, lack of reminders—can reduce uptake, especially when vaccination is not perceived as urgent. For this reason, some of the most effective interventions are not persuasive campaigns but service-design improvements. Mobile vaccination units, extended evening hours, walk-in appointments, and community-based clinics can make vaccination easier to access. These changes matter because convenience interacts with psychology: when a behaviour is simple and normal, people are more likely to follow through. Reducing logistical barriers can therefore convert “hesitant in practice” into “vaccinated in fact” without changing anyone’s ideology.

E The COVID-19 pandemic pushed vaccine hesitancy into global visibility and revealed how quickly uncertainty can affect health-system capacity. During the pandemic, vaccination was not only a personal choice but a collective strategy to reduce severe illness and maintain functioning hospitals. The crisis also highlighted the importance of health literacy—people’s ability to interpret health information, understand probabilities, and judge the credibility of sources. Where communication from authorities appeared inconsistent or opaque, distrust could grow. Conversely, transparency—clear explanations, acknowledgement of uncertainty when it exists, and honest updates as evidence evolves—can support confidence even when recommendations change. The pandemic also reminded policymakers that coverage is not maintained by short-term bursts of messaging. Sustained high vaccination rates require long-term investment in relationships, infrastructure and community engagement, so that vaccination becomes the easy, normative and trusted choice rather than a contested demand.

F The digital information environment has intensified the challenge. Online platforms allow misinformation and disinformation to circulate rapidly, often packaged in highly emotional narratives that spread faster than cautious scientific language. Algorithmic amplification can prioritise content that provokes outrage or fear, increasing exposure to dramatic personal stories over statistical summaries. In addition, social media networks can form echo chambers in which users repeatedly encounter the same claims, making minority views appear mainstream. This does not mean technology alone “causes” hesitancy; rather, it can magnify anxieties, reinforce cognitive bias, and provide social reinforcement for doubt. Once a claim becomes associated with group identity, correcting it is more difficult because the issue is no longer only factual. The platform architecture can therefore shape not just what people see, but how they feel about what they see, and whether they interpret public health advice as guidance or as interference.

G A classic illustration is the long-running claim that the MMR vaccine is linked to autism—an allegation that was thoroughly discredited by later research, yet remains socially persistent. The endurance of such stories reveals that people do not evaluate evidence in isolation. Trust in institutions, personal experience, and a sense of belonging can weigh as heavily as scientific consensus. As a result, simply repeating that a claim is false may fail to persuade, or may even deepen suspicion if it sounds dismissive. Effective communication often requires addressing underlying fear, recognising the emotional stakes, and explaining how safety monitoring works in understandable terms. Policy can also influence attitudes. Some jurisdictions require vaccination for school entry or tie certain benefits to immunisation status; these measures can raise uptake, but if introduced without engagement they may be perceived as coercive and fuel polarisation. Over time, the most durable gains tend to come from layered approaches: reliable service delivery, respectful dialogue, and institutional behaviour that consistently demonstrates competence and honesty. In that sense, vaccine confidence resembles an ongoing relationship, built through repeated experiences rather than a one-off campaign.

Antimicrobial resistance (AMR) is often described as a “silent pandemic” because it spreads gradually yet threatens to undermine some of the most basic assumptions of modern healthcare. AMR occurs when bacteria, viruses, fungi and parasites adapt in ways that allow them to withstand medicines that once killed them. Although resistance can emerge naturally through pathogen evolution, the speed and scale of the present problem are largely driven by human practice. When antimicrobial drugs are used too often or inappropriately, they exert powerful selective pressure, favouring organisms that carry resistance traits. If this process continues unchecked, infections that were once minor could become untreatable, and procedures that rely on dependable infection control—surgery, chemotherapy, intensive care, organ transplantation—could become far riskier than they are today. The reality of this threat is already visible in pathogens such as multidrug-resistant tuberculosis (MDR-TB) and carbapenem-resistant Enterobacteriaceae (CRE). Often dubbed “nightmare bacteria”, these organisms cause infections that are extremely difficult and costly to treat, and are associated with high mortality rates.

The underlying biology is straightforward but relentless. When an antibiotic is introduced into a mixed population of microbes, the most susceptible organisms are eliminated first. Resistant organisms, by contrast, remain alive and therefore survive, multiply, and gradually dominate. This is not a moral failing of microbes; it is a predictable outcome of selection. Problems arise when the drug exposure is unnecessary, too brief, or too broad. Over-prescription for viral infections, for example, accelerates resistance because antibiotics do nothing to the virus yet still pressure the bacterial communities living in and on the patient. Likewise, patients who stop treatment early can leave behind partially resistant survivors, and the next infection becomes harder to treat. The same logic applies to prophylactic use and routine “just in case” prescribing, where uncertainty in diagnosis pushes clinicians toward medication even when the probability of bacterial disease is low.

A second mechanism makes AMR especially difficult to contain: microbes are not restricted to passing resistance only to their direct descendants. Through horizontal gene transfer, bacteria can exchange genetic material—sometimes even across unrelated strains—rapidly spreading resistance traits through a microbial community. In practical terms, this means that once resistance genes become common in a hospital ward, a wastewater system, or an animal-rearing environment, they can be shared, recombined, and amplified. The problem is therefore not only clinical; it is ecological. Resistant organisms can circulate quietly, especially where epidemiological surveillance is limited, and may remain undetected until a cluster of treatment failures forces attention. In a world of travel, trade and dense urban networks, resistant strains can move between regions long before they appear in official statistics.

Agriculture complicates the picture further because it creates large, concentrated reservoirs in which antimicrobials are used at scale. In many systems, antibiotics have been deployed not only to treat illness in animals but also as routine prevention or to promote growth. When livestock are exposed repeatedly, resistant bacteria can proliferate in animals and spread outward. Humans can be exposed via direct contact, through water contaminated with animal waste, or through contaminated food moving along supply chains. Regulation in this arena is difficult precisely because the pathways cross farms, processing facilities, retailers, and borders. Effective control requires coordination and monitoring across multiple sectors, otherwise restrictions in one jurisdiction can be undermined by weak standards in another.

Efforts to improve prescribing practice face sociological hurdles as well as technical ones. Antimicrobial stewardship aims to ensure that the right drug is used, at the right dose, for the right duration, and only when genuinely indicated. However, prescribers often operate under time pressure, with ambiguous symptoms and incomplete information. Meanwhile, patients may arrive expecting a prescription as proof that their complaint is being taken seriously. In these interactions, antibiotics can become a symbol of care rather than a carefully rationed resource. Changing habits therefore requires more than issuing guidelines: it often depends on training, feedback systems, supportive workplace cultures, and communication strategies that help clinicians manage expectations without damaging trust.

Diagnostics are frequently called a missing link in the AMR response. A clinician who cannot rapidly distinguish viral from bacterial disease may prescribe “just in case”, especially if follow-up is uncertain. Rapid point-of-care testing could reduce unnecessary antimicrobial use and support targeted treatment, but developing devices that are accurate, cheap, quick, and scalable remains a technical challenge. Even when tests exist, integrating them into routine practice can be hard: clinics need equipment, staff training, supply chains, and funding models that reward careful diagnosis rather than speed alone. Without reliable diagnostics, many health systems remain stuck in a cycle where uncertainty drives broad prescribing, and broad prescribing fuels resistance.

The economic dimension introduces another layer of difficulty. New antibiotics are urgently needed because existing medicines are losing effectiveness, yet the market incentives to develop them are weak. This is a classic market failure: a new antibiotic is most valuable when it is held in reserve and used sparingly to preserve efficacy, but that conservation logic reduces sales volumes and therefore reduces profitability. Companies may prefer drugs for chronic conditions that guarantee long-term demand, rather than short-course antibiotics that stewardship programmes aim to restrict. As a result, many experts argue for alternative economic models, including public-private partnerships, subscription-style payments, or market entry rewards that detach revenue from volume while still encouraging innovation.

Because AMR links hospitals, farms, waterways and communities, many specialists argue that the only workable response is a One Health approach, which recognises that human health, animal health and environmental health are inseparable. Practical strategies include strengthening epidemiological surveillance, regulating agricultural use, enforcing stewardship in clinics, and investing in diagnostics and new treatments. Public messaging is also necessary, but it must be realistic: antibiotics are powerful tools, not universal solutions, and overuse imposes costs on everyone by accelerating resistance. Ultimately, AMR is not a problem that can be solved by one country or one sector in isolation. It is a collective-action challenge that demands sustained cooperation, consistent standards and a long-term shift in how societies value antimicrobial medicines.

A The world’s disease profile has been reshaped by a sweeping epidemiological transition. In many regions, the dominant threats to life are no longer acute infections but chronic, non-communicable diseases (NCDs), most notably cardiovascular disease, cancers, chronic respiratory disorders and diabetes. These conditions are not transmitted from person to person in the way that influenza or tuberculosis is. Instead, they develop over time through interacting genetic predispositions, physiological pathways, environmental exposures and behavioural patterns. As NCDs have risen, they have forced a rethinking of what health systems are for: services built around short episodes of infectious illness must increasingly deliver prevention, early detection and long-term management as core functions rather than optional add-ons. This shift is particularly consequential because NCDs now dominate mortality at the global level and, in many countries, account for the majority of health-system demand.

B The most influential drivers of the NCD surge are modifiable risk factors that spread with modernisation and globalisation. Tobacco use, diets high in salt, sugar and saturated fats, physical inactivity and harmful alcohol consumption remain central. Urbanisation often intensifies these risks by reshaping daily life: jobs become less physically demanding, transport becomes motorised, and affordable processed foods become widely available. Yet behaviour does not occur in a vacuum. Social conditions such as poverty, education, job insecurity and chronic stress can strongly shape exposure to risk and the capacity to avoid it. For this reason, NCDs can no longer be seen as “diseases of affluence”. They increasingly burden low- and middle-income countries, where resources for prevention and chronic care are often weakest, and where illness can strike in working-age populations, deepening economic vulnerability.

C The economic footprint of NCDs is vast, combining direct medical spending with indirect costs from disability and lost productivity. For families, long-term illness can translate into catastrophic health expenditure—spending so large it forces painful trade-offs between treatment and basic needs such as food or schooling. At the system level, the demands of chronic disease management require a departure from episodic models of care. Effective control depends on continuous monitoring, stable supplies of essential medicines (such as insulin or antihypertensives), and well-developed primary care capable of follow-up rather than crisis-only intervention. This, in turn, depends on health information systems that can track patients across time and facilities. In many regions, those forms of infrastructure remain underbuilt, meaning preventable complications accumulate and hospital costs rise.

D Because NCDs are shaped by long-term exposure to risk, prevention tends to be more cost-effective than late-stage treatment. Population-level policies—those that alter environments rather than targeting only individual willpower—often have the broadest reach. Tobacco taxation, plain packaging, and restrictions on marketing can reduce smoking rates at scale. Regulation can also reshape food environments through limits on trans fats and incentives or rules that reduce salt and added sugars in processed products. Urban planning can matter as much as clinics: safe pavements, reliable public transport, and green spaces can increase routine physical activity. Individual-level measures, such as screening for hypertension and diabetes, remain important, but they work best when affordable and integrated into accessible primary care. Public campaigns can raise awareness, yet they are usually insufficient without policies that make healthier choices easier to sustain.

E The policy challenge is therefore not confined to health ministries. A multisectoral response is required because the determinants of NCD risk are embedded in finance, trade, agriculture, education, labour policy and urban design. This is why many experts call for a whole-of-government approach, in which multiple departments align incentives to reduce risk rather than inadvertently amplifying it. A central obstacle is the commercial determinants of health: corporate practices that promote unhealthy products through pricing strategies, branding, lobbying and extensive distribution networks. Regulation can provoke sustained resistance from powerful commercial actors, particularly when reforms threaten profits or market share. Nevertheless, international commitments reflect the scale of the threat. The Sustainable Development Goals include a target to reduce premature NCD mortality by one-third by 2030, a goal that implies long-term political commitment and consistent coordination across sectors.

F NCD risk also accumulates across the life course, which complicates both prevention and politics. Early-life nutrition, exposure to air pollution, and repeated experiences of stress can shape susceptibility to cardiovascular disease and diabetes decades later. In practical terms, this means some of the highest-yield policies are those aimed at children, even though their benefits are delayed. Healthier school meals, restrictions on marketing sugary foods to young audiences, and safe routes that enable walking or cycling can reduce long-term risk trajectories. The difficulty is that political systems often favour short-term results, while life-course prevention is inherently longitudinal. Yet without these upstream investments, later healthcare costs rise and inequalities become harder to reverse.

G Inequality becomes even more visible once disease develops. The ability to obtain diagnosis, start treatment promptly, and remain on continuous medication differs sharply by geography and income. Interruptions in care—caused by medicine stock-outs, clinic fees, long travel distances or unstable employment—can lead to preventable complications such as stroke, kidney failure or diabetic blindness. Where primary care is weak, people may delay seeking help until symptoms become severe, making treatment more complex and costly and placing avoidable strain on hospitals. NCDs therefore function not only as medical conditions but also as stress tests of social systems: they expose how gaps in access convert manageable illness into disability.

H Tracking progress depends on measurement, yet many countries lack robust systems to monitor risk and control at the population level. Reliable surveillance is needed to see whether blood pressure is being controlled, whether diabetes management is improving, and whether tobacco consumption is truly declining. Without consistent indicators, governments may underestimate the scale of the NCD burden, allocate resources poorly, or miss failures among vulnerable groups underrepresented in surveys. Data also matters for accountability: population-level interventions may take years to show effects, so credible indicators help sustain policy attention and reveal whether reforms are reaching those most at risk. In this sense, measurement is not a technical afterthought but a prerequisite for effective governance in an era where chronic disease dominates.